The Delaware facility will ensure a domestic supply of biologic drugs including the cancer drug Keytruda.

Merck (NYSE:MRK) has broken ground on a $1 billion facility in Wilmington, Delaware, becoming the latest pharmaceutical company to boost domestic investment as industry-targeted tariffs loom.

According to Merck, the total investment is now expected to be over $1 billion, with 500 full-time jobs and 4,000 ...

Merck Animal Health is investing $895 million in a De Soto new facility, which will bring hundreds of jobs. It’s a huge ...

Seven weeks after opening a new $1 billion vaccine manufacturing facility in North Carolina, Merck has revealed that it is breaking ground on another $1 billion plant—this one in Wilmington ...

A new manufacturing plant in De Soto will be a Center of Excellence for the global company, along with expanded R&D ...

Shares fell after the company cut its full-year guidance on the back of challenging macroeconomic conditions and ...

Here’s what to know. In February, Merck officials presented to Delaware’s Council of Development Finance to make their case for receiving a grant to invest in their ambitious project.